Charles Davis is an Infectious Disease physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
22 S Greene St
Baltimore, MD 212011544
Telephone
410-706-4608Registry record last updated 17 Nov 2010.
Clinical trials
- A Safety and Immunogenicity Trial of IHV01
Sponsor: University of Maryland, Baltimore
- Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study
Sponsor: University of Maryland, Baltimore
- A Two Year Study of the Clinical Efficacy of the Combination of Emtricitabine, Tenofovir, and Nevirapine
Sponsor: University of Maryland, Baltimore
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
56.4%Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor34.6%Triumeq100%Part D<11 patientsHuman Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor21.8%Atripla100%Part D<11 patientsCardiovascular
43.6%Calcium channel blocker29.5%Amlodipine Besylate100%Part D<11 patientsAngiotensin receptor blocker (ARB)14.1%Losartan-Hydrochlorothiazide100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2011–2014 per NIH RePORTER. The latest:
- Institute of Human Virology Clinical Trials Unit
University of Maryland Baltimore
FY2014$72,593UM1AI069447 - Institute of Human Virology Clinical Trials Unit
University of Maryland Baltimore
FY2013$741,291UM1AI069447 - Institute of Human Virology Clinical Trials Unit
University of Maryland Baltimore
FY2012$788,268UM1AI069447
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”